Many longitudinal studies (e.g. observational studies and randomized clinical trials) have collected multiple rating scales at each visit in the form of patient-reported outcomes (PROs) in the close unit interval [0,1]. We propose a joint modeling framework to address the issues from the following data features: (1) multiple correlated PROs; (2) the presence of the boundary values of zeros and ones; (3) extreme outliers and heavy tails; (4) the PRO-dependent terminal events such as death and dropout. Our modeling framework consists of a multivariate augmented mixed-effects sub-model based on Beta rectangular distributions for the multiple longitudinal outcomes and a Cox model for the terminal events. The simulation studies suggest that in the presence of outliers, heavy tails, and dependent terminal event, our proposed models provide more accurate parameter estimates than the joint model based on Beta distributions. The proposed models are applied to the motivating Long-term Study-1 (LS-1 study, n ¼ 1741) of Parkinson's disease patients.
total of 1741 patients with early PD were randomly assigned to receive either placebo or creatine. In-person evaluations were conducted at baseline and then annually beginning at 12 months, until the last enrolled participant has completed 5 years of observation. When the LS-1 study was terminated in August 2013 due to the futility of creatine, many participants had extended follow-up (mean 3.9 years, maximum 6.4 years). The LS-1 study represents the largest cohort of patients with early treated PD ever enrolled in a clinical trial and the details of this study can be found in Elm et al. 20 The primary outcomes of interest are EQ-VAS and PDQ-39 scales in this article. During the follow-up, 78 and 323 individuals died and dropped out of the study, respectively. We define a composite endpoint and time to death or dropout as the terminal event. Hence, we observe 401 occurrences of the terminal event in the LS-1 study. Figure 1 (left panels) displays the histogram of the EQ-VAS and PDQ-39 scores based on all individuals. The presence of a small amount of boundary values (168 occurrences of 100 s in EQ-VAS and 109 occurrences of 0 s in PDQ-39 out of 8227 observations, or 2.04% and 1.32%, respectively), if unaccounted for, is a critical issue for Beta or BR regression models because the boundary values 0 and 1 are out of the supports of Beta and BR distributions. Figure 1 (right panels) displays the longitudinal profiles of the EQ-VAS and PDQ-39 scores of 50 randomly selected individuals. Because PD is a slow progression disease, it is unexpected to observe sudden value change in the outcome variables such as EQ-VAS and PDQ-39, as indicated by the nearly horizontal lowest smooth curve (black solid lines), computed based on all individuals. However, sudden value changes are observed in both the EQ-VAS and PDQ-39 scores (indicated by the black cycles) in some individuals. Hence, these observations are potential outliers. We divide the original EQ-VAS and PDQ-39 scores by 100 to rescale them as proportional responses confined in the close unit interval [0, 1]. We are interested in examining the effect of outliers, as well as the boundary values of 0 and 1, on the inference of regression models based on the Beta and BR distributions, while accounting for the potential dependent terminal event.
Model and estimation 3.1 Beta and BR distributions
In this section, we first provide a brief review of the reparameterized Beta distribution 4 . A random variable Y follows a Beta distribution if the probability density function (pdf) in terms of its mean and precision parameter is given by
where 0 < y < 1, 0 < < 1, and > 0, E(Y) ¼ and Var(Y) ¼ (1 À )/(1 þ ). It is worth mentioning that a natural parameterization of the Beta distribution is via two shape parameters, i.e. ¼ and ¼ (1 À ), and hence Y $ Beta(,). But we adopt the notation Y $ Beta(, (1 À )) to facilitate the regression analysis on the mean . A Beta regression model can be defined under a GLM framework by linking the subject-specific mean i and covariates X i as logit( i ) ¼ X i b. The precision parameter can be either constant or log-transformed and then regressed on covariates. The BR distribution is a mixture distribution consisting of a Beta distribution and a uniform (rectangular) distribution between 0 and 1. Its pdf with support (0, 1) is given by f ðY ¼ yj, , pÞ ¼ p þ ð1 À pÞBð yj, Þ, where 0 p 1 is the mixture probability, and Bð yj, Þ is the pdf of the Beta distribution as in (1) . The BR distribution is denoted as Y $ BR(,,p). If p ¼ 1, the BR distribution reduces to the uniform (rectangular) distribution between 0 and 1 and if p ¼ 0, it reduces to the Beta distribution Bð yj, Þ. The mean and variance of the BR distribution are EðYÞ ¼ ð1 À pÞ þ p 2 ¼ and VarðYÞ ¼ ð1ÀÞ 1þ ð1 À pÞ½1 þ pð1 þ Þ þ p 12 ð4 À 3pÞ.
To conduct the regression analysis for the mean of the BR distribution, we do the following reparameterization: 12 Then, the pdf of the reparameterized BR distribution is
for y 2 (0, 1). We denote the reparameterized BR distribution (2) as Y $ BR(,,), where is the mean, is the precision parameter, and is a shape parameter controlling the thickness of the tails. When the mixture probability p ¼ 1, then ¼ 1 and ¼ 0.5, the BR distribution reduces to the uniform (rectangular) distribution between 0 and 1.
When p ¼ 0, then ¼ 0 and ¼ , the BR distribution reduces to the Beta distribution. In general, when 0 < p < 1, then 0 < < 1, the BR distribution has heavier tails than its Beta distribution counterpart. To visualize this, Figure 2 displays the density functions of various BR distributions with different values of , , and . It suggests that when > 0, the BR distribution has heavier tails than the corresponding Beta distribution. Similar to the Beta regression model, the BR regression model can be defined as logit( i ) ¼ X i b and the precision parameter can be either constant or regressed on covariates.
Augmented BR regression model
In this section, we generalize the BR regression model in Section 3.1 to account for the multivariate longitudinal data structure and the boundary values at zero and one. Let y ijk 2 [0, 1] be the observed outcome kðk ¼ 1, . . . , K, e.g. outcomes are EQ-VAS, PDQ39 and K ¼ 2) at visit j ð j ¼ 1, . . . , J i , where j ¼ 1 is baseline and J i is the number of visits) from individual iði ¼ 1, . . . , I, where I is the number of individuals). Let y ij ¼ ð y ij1 , . . . , y ijk , . . . , y ijK Þ 0 be the vector of observation for individual i at visit j, and let y i ¼ ðy 0 i1 , . . . , y 0 iJ i Þ 0 be the outcome vector for individual i across visits, and let y ¼ ðy 0 1 , . . . , y 0 I Þ 0 be the observed outcome vector from all individuals. For outcome k, we propose an augmented BR (ABR) model, denoted by Y ijk $ ABR(p 0ijk , p 1ijk , ijk , k , k ), whose pdf follows:
where
Þ is the reparameterized BR density function given in (2) . Next, we propose the ABR regression model by regressing the covariates onto p 0ijk , p 1ijk , and the mean ijk , which are transformed by appropriate link functions: where the covariate vector X i0 , X i1 , and X i2 can be identical or different and they include covariates of interest (e.g. treatment assignment) and potential confounding variables (e.g. individual characteristics and socioeconomic status) from individual i. We adopt the logit link function for all three models, while other link functions (e.g. probit and complementary log-log) can also be used. We assume that the random effects vector u ik ¼ (u i0k ,u i1k ,u i2k ) 0 follows a multivariate normal distribution N(0,D k ), with covariance matrix D k . When there are a total of K outcomes, the inter-outcome correlation can be modeled by assuming that the random effects vector u i ¼ ðu 0 1 ; . . . ; u 0 K Þ 0 follows a multivariate normal distribution with mean 0 and covariance matrix D (a 3K Â 3K matrix).
The proposed ABR regression model can be easily modified to accommodate various features in the data. For example, an augmented Beta (AB) model for outcome k is obtained by replacing the BR density f ðY ijk ¼ y ijk j ijk , k , k Þ with the Beta density in (1) or equivalently by setting k ¼ 0. If outcome k only contains zeros or ones, then the ABR regression model (4) can be simplified by removing the parameter p 0ijk or p 1ijk from model (3) . On the other hand, if there are neither zeros nor ones observed in outcome k, we can let p 0ijk ¼ p 1ijk 0, then the ABR regression model reduces to either the mixed effects BR regression model or the mixed effects Beta regression model (if k ¼ 0). Moreover, additional random effects (e.g. random slopes) can be easily incorporated in model (4) .
Let the parameter vector for outcome k be ? 
where I(Á) denotes the indicator function. Let t i denote the time to the terminal event for individual i, i (1 if the terminal event is observed and 0 if not) denote the censoring indicator for t i , and X i denote the vector of possible risk factors. Vector X i can share part of or all covariates in vectors X i0 , X i1 , and X i2 . The hazard of having a terminal event at time t i is
; k2 Þ 0 are unknown parameters, and 0 (t i ) is the baseline hazard function. The associated survival function is
Conditional on the random effects vector u i , y i is assumed to be independent of t i . The full likelihood of the joint model for individual i is
where p(u i ) is the density function of u i , the parameter vector ? ¼ ð? 0 y , ? 0 s Þ 0 . The ''cross-equation correlation'' between models (4) and (6) is introduced by the subject level random effects vector u i . Specifically, for the outcome PDQ-39, negative parameter k0 indicates that the individuals with higher probabilities of being at 0 (good QoL) are less likely to die or drop out of the study. Similarly, positive parameter k2 suggests that the individuals with lower PDQ-39 values (better QoL) tend to have lower risk of death or dropout. Similar interpretation can be made to the parameters k1 and k2 for the outcome EQ-VAS. We refer to the proposed joint modeling framework assuming the BR and Beta distributions as models JM BR and JM Be , respectively. In order to illustrate the need of joint modeling the longitudinal measurements and survival events, we consider the reduced models which assuming that the survival time is independent of the longitudinal outcomes. We refer to the reduced models assuming the BR and Beta distributions as models RM BR and RM Be , respectively.
Bayesian inference 4.1 Prior specification
The full likelihood formulation in model (7) involves unspecified baseline hazard function 0 (Á). We adopt a piecewise constant function to approximate 0 (Á). It has been shown that survival models using a piecewise constant baseline hazard function yield good estimators for both fixed effects and frailty, 21, 22 although fixed cut points need to be specified a priori. It is more flexible than the a priori choices of baseline hazard distribution (e.g. Weibull distribution) and it retains enough model structure. 23 Specifically, we divide the follow-up period into m intervals by every 1/mth quantiles denoted by 1 , 2 , . . . , m and 0 ¼ 0 or the smallest failure time. The baseline hazard vector is g ¼ ð g 1 , g 2 , . . . , g m Þ, and the piecewise constant baseline hazard function is defined as
To make inference on the unknown parameter vector ?, we use Bayesian inference based on Markov chain Monte Carlo (MCMC) posterior simulations. We use vague priors on all elements in the parameter vector ?. Specifically, the prior distributions of all elements in the regression parameter vectors x and b are N(0, 100), where
We use the prior distribution Gamma(0.001, 0.001) for the precision parameter k and all of the variances in the covariance matrix D. We use Uniform(À1, 1) prior distribution for all of the correlation coefficients in matrix D and Uniform(0, 1) prior distribution for the shape parameter k . We have investigated other selections of vague prior distributions and have obtained very similar results in both the simulation studies and the application.
The posterior samples are obtained from the full conditional of each unknown parameter using Hamiltonian Monte Carlo (HMC) 24, 25 and No-U-Turn Sampler (NUTS). 26 The HMC and NUTS samplers are implemented in Stan, which is a probabilistic programming language implementing statistical inference with HMC and NUTS samplers. The model fitting is performed in STAN (version 2.5.0) 27 by specifying the full likelihood function and the prior distributions of all unknown parameters. For large datasets, STAN may be more efficient than BUGS in achieving faster convergence and requiring smaller number of samples. 26 To facilitate easy reading and implementation of the proposed models, a sample STAN code for fitting model JM BR has been posted in the online supplement (available at: http://smm.sagepub.com/).
To monitor Markov chain convergence, we use history plots and view the absence of apparent trend in the plots as evidence of convergence. We run multiple chains with diffuse initial values and ensure the scale reductionR of all parameters are smaller than 1.1. 28 
Bayesian model selection and influence diagnostics
There are a wide variety of model selection criteria in Bayesian inference. Because of the mixture framework in our model, we use the DIC 3 measurement. 29 The DIC 3 is defined as 
where p(M l ) is the prior probability of model M l , where l ¼ 1, 2, pðM l jyÞ is the posterior probability of model M l , and pðyjM l Þ is the predictive probability of observing data y under model M l , and pðyjM l Þ ¼ R f ðyj? l , M l Þ pð? l jM l Þd? l , where pð? l jM l Þ is the prior distribution for parameter vector ? l under model M l . When BF 12 > 150, decisive evidence is shown in favor of model M 1 ; when BF 12 is between 20 and 150, strong evidence is shown in favor of model M 1 . 31 To avoid the integral involved in computation of BF, the Laplace-Metropolis estimator based on the normal distribution 32 is adopted to approximate the predictive probability. Specifically, pðyjM l Þ % ð2Þ d l =2 jD l j 1=2 f ðyj? l , M l Þ pð? l jM l Þ, where d l is the number of the parameters in parameter vector ? l , D l is the posterior covariance matrix of ? l , ? l is the posterior mean of ? l , pð? l jM l Þ is the prior probability of parameters evaluated at ? l , and f ðyj? l , M l Þ is the likelihood from model M l when parameters are at the posterior mean values.
Moreover, the widely used criteria conditional predictive ordinate (CPO) 30 
Simulation studies
In this section, we conduct an extensive simulation study with three settings to compare the performance of the proposed joint models JM BR and JM Be . The simulated data structure is similar to the motivating LS-1 study. Specifically, in all three settings, we generate 200 datasets with sample size N ¼ 600 individuals and seven visits, i.e., baseline and six follow-up visits, J i ¼ 7 with the time vector t i ¼ ðt i1 , t i2 , . . . , t i7 Þ 0 ¼ ð0, 1, 2, 3, 4, 5, 6Þ 0 . We generate two continuous proportional outcome (K ¼ 2) restricted in the interval (0, 1] (assuming that both outcomes can reach boundary value at 1, but not at 0). We consider one covariate x i taking value 0 or 1 each with probability 1/2 to mimic the treatment assignment. In all settings, the datasets are simulated from the following models:
We set the regression coefficient vectors to be u 1 ¼ ðÀ1:5, À 0:5Þ 0 , u 2 ¼ ðÀ1, À 1Þ 0 , b 1 ¼ ð1:5, À 0:5, À 0:1, 0:2Þ 0 , b 2 ¼ (1,À1,À0.2, 0.5) 0 , and c ¼ À1. We set the precision parameters to be 1 ¼ 10 and 2 ¼ 5. The random effects vector u i ¼ (u i11 ,u i21 ,u i12 ,u i22 ) 0 is simulated from a multivariate normal distribution with mean 0 and covariance matrix D generated with the following parameters: 2 11 In all three settings, we assume that the two longitudinal outcomes are associated with the survival outcome with the parameters l ¼ ðl 0 1 , l 0 2 Þ 0 ¼ ð0:2, 0:4, 0:5, 0:4Þ 0 . We apply the Bayesian framework in Section 4 to obtain inference. To determine the burn-in iterations and assess the MCMC convergence and mixing properties, we examine the trace plots and the autocorrelations. We find that the chains converge reasonably fast and all achieve stationarity within 2000 iterations withR of all parameters smaller than 1.1. We run two parallel MCMC chains with diverse initial values and choose 2000 iterations for burn-in and the inference is based on the subsequent 2000 iterations from both chains.
In simulation setting I, we simulate data from model JM Be assuming no outliers and extremal events around the tail-areas in both longitudinal outcomes ( 1 ¼ 2 ¼ 0). Table 1 displays bias (the average of the posterior means minus the true values), standard deviation (SD, the standard deviation of the posterior means), coverage probabilities (CP) of 95% equal-tail credible intervals, and root mean squared error (RMSE) from models JM Be and JM BR . The results suggest that when data come from model JM Be , both models JM Be and JM BR generate comparable results with very small bias and RMSE, and the coverage probability being reasonably close to 0.95. Under model overparameterization, the estimates of the shape parameters 1 and 2 from model JM BR are correctly close to zero, suggesting that this model is still a reasonable choice in the absence of outliers.
In simulation setting II, we simulate data from model JM BR with some outliers and extremal events around the tail areas in both longitudinal outcomes by setting the share parameters 1 ¼ 0. In simulation setting III, we evaluate the influence of outliers and extremal events around the tail areas. This simulation setting is similar to setting I, but we contaminate 1% of the randomly selected observations from both longitudinal outcomes with high scores (0.9, 1) by decreasing Á units ð y Ã ijk ¼ y ijk À Á, and Á ¼ 0:8Þ. We then fit joint models JM Be and JM BR (Table 3 ). Comparing with model JM Be , model JM BR provides parameter estimates with smaller bias (e.g. À 0.071 versus À 0.126 for 10 ) and smaller RMSE (e.g. 0.089 versus 0.136 for 0 ), suggesting that model JM BR can effectively control the outlying observations.
In conclusion, the simulation results suggest that in the absence of outliers and extremal events around the tail areas, models JM Be and JM BR give comparable results after accounting for dependent censoring. In the presence of outliers and extremal events around the tail areas, model JM BR provide more accurate parameter estimates than model JM Be .
Application to the LS-1 study
In this section, we apply the proposed joint models (JM Be and JM BR ) as well as the reduced models (RM Be and RM BR ) to the motivating LS-1 study. For all results in this section, we run two parallel MCMC chains with overdispersed initial values and run each chain for 4000 iterations. The first 2000 iterations are discarded as burn-in and the inference is based on the remaining 2000 iterations from each chain. Good mixing properties of the MCMC chains for all model parameters are observed in the trace plots. The scale reductionR of all parameters are smaller than 1.1. To specify the baseline hazard functions 0 (t i ), we divide the time to death or dropout into M ¼ 3 intervals by every 1/Mth quantiles. We have also explored other selections of M and the results are very similar.
In the data analysis, we divide both the variables EQ-VAS and PDQ-39 by 100 to rescale it to the interval [0, 1]. Because there is no occurrence of 0 in the variable EQ-VAS (k ¼ 1) and no occurrence of 1 (or 100 in the original scale) in the variable PDQ-39 (k ¼ 2), we fit the following model:
Þ 0 , and X i ¼ x i , x i is the treatment assignment variable (1 for creatine, and 0 for placebo), t ij is the visit time in years, and the random effects vector u i ¼ ðu i1 , u i2 , u i3 , u i4 Þ 0 $ MVNð0, DÞ, where D is a covariance matrix of dimension 4 Â 4 with variance 2 1 , . . . , 2 4 on the diagonal and correlation coefficients mn with 1 m < n 4. Table 4 compares models JM Be , JM BR , RM Be and RM BR using the model selection criteria 31 Thus, we select model JM BR as the final model. Moreover, both joint models JM Be and JM BR outperform their reduced model counterparts RM Be and RM BR , respectively, which indicates that joint modeling is essential and improves the model fitting.
To determine the presence of possible outlying observations, the K-L divergence measure of every observation is presented in Figure 3 for models JM Be (left panels) and JM BR (right panels). Model JM Be identifies many observations as potential outliers, whose K-L divergence measures are larger than 3. However, using model JM BR , there seem to be no influential observations with all K-L divergence measures smaller than 3. This figure suggests that model JM BR can effectively control the potential outlying observations. Table 5 displays the posterior means, standard deviations (SDs), and the 95% equal-tailed credible intervals from the joint models JM Be and JM BR . Parameter estimates are noticeably different from two models, although the same set of parameters are identified for statistical significance. For the creatine patients, the odds ratio of the probability of reporting 1 (best imaginable health, or 100 in the original scale) in the EQ-VAS score is 0.605 (exp(À0.502), 95% CI: [0.350, 1.040]) comparing with the placebo patients, in model JM BR , versus 0.602 (exp(À0.508), 95% CI: [0.353, 1.034]) in model JM Be . Similarly, the odds ratio of the probability of reporting 0 in the PDQ-39 score (best QoL) for the creatine patients is 0.869 (exp(À0.140), 95% CI: [0.497, 1.534]) comparing with the placebo patients, in model JM BR , versus 0.839 (exp(À0.176), 95% CI: [0.480, 1.554]) in model JM Be . The parameters under the sections of conditional mean represent the effects of the covariates on the means of the EQ-VAS and PDQ-39 scores conditional on not being on the boundaries. Thus, negative parameters suggest deterioration in patients' global assessment of their health represented in the EQ-VAS score, while positive parameters suggests deterioration in patients' QoL represented in the PDQ-39 score. Conditional on other covariates and the random effects, parameter interpretation can be expressed in terms of the covariate effect on the odds ijk 1À ijk (rescale) or 100 ijk 100À100 ijk in the original scale for model JM BR . Specifically, for the creatine patients, the ratio between the expected EQ-VAS score ij1 and the difference to perfect health (1 À ij1 ) is 0.953 (exp(À0.048), 95% CI: [0.890, 1.022]) times the ratio of the placebo patients. For one year increase in time, the ratio between the expected EQ-VAS score and the difference to perfect health decreases by 7.6% (1 À exp(À0.078), 95% CI: [0.067, 0.085]). The regression parameters for the PDQ-39 scores can be interpreted in a similar way. The fact that the estimates of the shape parameters 1 and 2 are 0.110 (95% CI: [0.093, 0.128]) and 0.040 (95% CI: [0.027, 0.056]) suggests the existence of some potential outliers in the EQ-VAS score, but possibly not in the PDQ-39 score. Moreover, creatine has insignificant effects on the risk of death or dropout, that is, the time to death or dropout for the creatine patients is estimated to be 1.026 times (exp(0.026), 95% CI: [0.831, 1.261]) that of the placebo patients. The findings of insignificant creatine effects are consistent with the primary paper of the LS-1 study. 39 There is no significant association between the longitudinal outcomes EQ-VAS and PDQ-39 and the survival time, as indicated by the insignificant parameters 1 , 2 , 3 , and 4 . The regression parameters in model JM Be can be interpreted in a similar way. Table 5 also suggests strong correlation both within and between the two longitudinal outcomes EQ-VAS and PDQ-39 as indicated by the relatively large correlation coefficients . Specifically, patients with higher probability of being 1 in the EQ-VAS score (perfect health) are more likely to report high EQ-VAS values (good health) as indicated by large positive significant 12 , more likely to report 0 in the PDQ-39 score (best QoL) as indicated by large positive significant 13 , and less likely to report high PDQ-39 values (worse QoL) as indicated by large negative significant 14 . Similarly, patients with higher probability of reporting high EQ-VAS values are more likely to report 0 in the PDQ-39 score (large positive significant 23 ) and less likely to report high PDQ-39 values (large negative significant 24 ). Lastly, patients with higher probability of being 0 in the PDQ-39 score are less likely to report high PDQ-39 values (large negative significant 34 ). 
Discussion
Health-related QoL variables in the form of PROs have become increasingly common in clinical trials of Parkinson's disease (PD) and other neurodegenerative diseases (e.g. Alzheimer's disease, Huntington's disease) in the past three decades, 40 e.g. EQ-VAS and PDQ-39 scores in the motivating LS-1 study. When the survival benefit of a treatment is small or modest, improvement in QoL for patients is sometimes more important than modest survival benefit in making treatment decisions. 41 Because there is neither a cure nor a treatment that can effectively slow the progression of PD, it is essential to model longitudinal PROs related to PD patients' QoL and terminal events through a joint modeling framework to gain insight into their correlation. Moreover, some longitudinal PROs such as variables EQ-VAS and PDQ-39 are constrained in the closed interval [0, 1] after rescaling. Although traditional Gaussian models works well for the normally distributed continuous outcomes with no boundary, models based on Beta distributions are more appropriate in this scenario to avoid out of bound predictions. To better analyze the data with multiple PROs in the close unit interval [0, 1], we develop a joint modeling framework to address the following data complexities: (1) multiple correlated PROs; (2) the presence of the boundary values of zeros and ones; (3) extreme outliers and heavy tails; (4) the PROs-dependent terminal events such as death and dropout. Our modeling framework consists of a multivariate augmented BR regression sub-model for the multiple longitudinal outcomes and a Cox proportional hazard sub-model for the dependent censoring event. Two submodels are linked by shared random effects denoting subject-specific characteristics. We adopt Bayesian inference framework based on MCMC simulation for parameter estimation. The extensive simulation study suggests that in the presence of outliers and heavy tails, the proposed joint modeling framework based on the BR distributions (model JM BR ) improves the accuracy of parameter estimates, while the joint modeling framework based on the Beta distribution (model JM Be ) provides parameter estimates with large bias and RMSE and poor coverage probabilities. We apply the proposed models to the motivating LS-1 study dataset. Model JM BR has a better fit than model JM Be (which does not account for the heavy tails and outliers), and the reduced models RM Be and RM BR (which assume independence between the survival time and longitudinal outcomes). The treatment creatine has insignificant effects in the probabilities of being at the boundaries, in the mean scores of both EQ-VAS (global health assessment) and PDQ-39 (quality of health) variables, and in the survival time. The findings of insignificant creatine effects are not surprising because the LS-1 study was terminated early for futility based on results of a planned interim analysis. 39 However, our final model JM BR detects a significant time effect on both EQ-VAS and PDQ-39 variables and a significant time and treatment interaction effect on outcome PDQ-39, which is a new finding and is worth further investigation. Moreover, our model provides unique clinical insight into the correlation between PROs (interoutcome correlation). Although our data example only contains one boundary value for each outcome, the proposed JM BR model is general and flexible to make it widely applicable to longitudinal outcomes with the support of [0, 1] (either with or without rescaling), in the presence of outcome-dependent survival events, because it can accommodate various data features, e.g. either with or without boundary observations and outliers and heavy tails. The proposed model and Bayesian inference can be easily implemented by the publicly available software packages such as BUGS and STAN. The generic structure of BUGS and STAN facilitates flexibility in model specification. We expect that the STAN code we provide would help make our model easily accessible to applied researchers.
There are some limitations in our proposed model that we will address in our future study. This article only considers a composite endpoint (death or dropout) as a single type terminal event. The covariate effects for the risks of these two events can be different. The proposed joint model can be extended to accommodate competing risks survival data. Moreover, relaxing the proportionality assumption in the Cox model by exploring other survival model choices such as accelerated failure time model warrants further investigation. Some researchers 42, 43 have reported that the statistical inference of joint models is generally robust to the departure from the normality assumption. It is of interest to investigate our joint models' performance when the underlying random effects distribution is symmetric non-normal or even asymmetric. In addition, the random effects variance is assumed to be homogeneous (same for all individuals). However, the random effects variance may depend on subject-specific characteristics and is thus heterogeneous. Ignoring the heterogeneity can result in biased estimates. 44, 45 As a future direction, we would address the issues of non-normal, heterogeneous, or even nonparametric random effects 46 in the proposed joint modeling framework.
